探索在肝移植中将边际捐赠者与低功能接受者匹配的可行性
Miho Akabane1, Yuki Imaoka1, Toshihiro Nakayama1
1Division of Abdominal Transplant, Department of Surgery, Stanford University Medical Center, Stanford, California, USA.
Clinical transplantation
|March 10, 2025
概括
肝移植接受者功能不佳,移植的存活率更差,特别是与边际捐赠者. 老年接受者 (65岁以上) 在移植后功能下降的风险更高.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 移植医学 移植医学
- 器官捐献者研究 器官捐献者研究
背景情况:
- 在肝移植 (LT) 候选人中存在功能变异,具有类似的末期肝病模型 (MELD) 3.0分数.
- 边缘捐赠者移植对LT后功能和预后的影响受到接受者的LT前功能的影响.
研究的目的:
- 研究将肝移植接受者与低功能与边际捐赠者匹配对移植存活 (GS) 的影响.
- 为了评估对LT后功能的影响,当功能受损的接受者接受边缘移植时.
主要方法:
- 从移植受体科学注册表 (SRTR) 的数据分析.
- 基于估计的淋巴球过率 (eGFR) 的LT前功能分类:低 (<30毫升/分钟/1.73米2),高 (≥30毫升/分钟/1.73米2).
- 边际捐赠者的定义基于包括心脏病死亡后捐赠,年龄≥65岁,严重巨病 (≥30%),或BMI≥40kg/m2等标准.
- 主要结果:对LT后3年的GS进行比较. 二次结果:在1-3个月后对LT后的eGFR进行评估.
主要成果:
- 与高eGFR (p <0.01) 患者相比,低LT前eGFR的受体3年后GS显著降低 (p <0.01).
- 来自边际捐赠者的器官与三年GS显著减少有关 (p < 0.01),即使在相同的MELD 3.0类别内.
- 较低的LT前EGFR增加了LT后功能恶化的风险,特别是在边际捐赠者身上. 接受者年龄超过65岁是LT后功能下降的重要危险因素 (OR 3.34;p = 0.03).
结论:
- 肝移植接受者具有较低的LT前eGFR,特别是从边际捐赠者接受移植时,移植的存活率显著下降.
- 65岁以上的接受者年龄是使用边际捐赠者时LT后功能恶化的风险指标.
- 仔细的捐赠者-接受者匹配是至关重要的,特别是在接受者前LT功能受损和考虑边缘移植时.
相关概念视频
Tissue Transplantation
322
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
322
Bone Marrow Sampling and Transplants
270
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
270


